A-350619: A novel activator of soluble guanylyl cyclase

Life Sciences

Volumn 72, Issue 9, 2003, Pages 1015-1025

  Miller, Loan N ^a   Nakane, Masaki ^a   Hsieh, Gin C ^a   Chang, Renjie ^a   Kolasa, Teodozyi ^a   Moreland, Robert B ^a   Brioni, Jorge D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Activator; Nitric oxide; Sodium nitroprusside; Soluble guanylyl cyclase; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; ACRYLAMIDE DERIVATIVE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HEME; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG ACTIVITY; DRUG BINDING SITE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME REGULATION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; MALE; NONHUMAN; OXIDATION; PENIS ERECTION; RABBIT; RAT; SEXUAL DYSFUNCTION; SOLUBILITY;

ACRYLAMIDES; ANIMALS; CELLS, CULTURED; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; ENZYME INHIBITORS; GUANYLATE CYCLASE; HUMANS; INDAZOLES; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; PENILE ERECTION; RABBITS; RATS; RATS, WISTAR; SPODOPTERA;

EID: 0037449385     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02361-5     Document Type: Article

References (37)

1. Murad F. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate. Journal of American Medical Association. 276(14):1996;1189-1192.
2. Davis K.L., Martin E., Turko I.V., Murad F. Novel effects of nitric oxide. Annual Review of Pharmacology and Toxicology. 41:2001;203-236.
3. Bult H., Herman A.G., Matthys K.E. Antiatherosclerotic activity of drugs in relation to nitric oxide function. European Journal Pharmacology. 375(1-3):1999;157-176.
4. Janero D.R. Nitric oxide (NO)-related pharmaceuticals: contemporary approaches to therapeutic NO modulation. Free Radical Biology and Medicine. 28(10):2000;1495-1506.
5. Moreland R.B., Hsieh G., Nakane M., Brioni J.D. The biochemical and neurologic basis for the treatment of male erectile dysfunction. Journal of Pharmacology and Experimental Therapeutics. 296(2):2001;225-234.
6. Brioni J.D., Nakane M., Hsieh G.C., Moreland R.B., Kolasa T., Sullivan J.P. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. International Journal of Impotence Research. 14(1):2002;8-14.
7. 2+-ATPase in skeletal muscle. Biochemical Journal. 340(Pt 3):1999;657-669.
8. Kamisaki Y., Waldman S.A., Murad F. The involvement of catalytic site thiol groups in the activation of soluble guanylate cyclase by sodium nitroprusside. Archives of Biochemistry and Biophysics. 251(2):1986;709-714.
9. Nakane M., Murad F. Cloning of guanylyl cyclase isoforms. Advances in Pharmacology. 26:1994;7-18.
10. Nakane M., Arai K., Saheki S., Kuno T., Buechler W., Murad F. Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lung. Journal of Biological Chemistry. 265(28):1990;16841-16845.
11. Buechler W.A., Nakane M., Murad F. Expression of soluble guanylate cyclase activity requires both enzyme subunits. Biochemical and Biophysical Research Communications. 174(1):1991;351-357.
12. Ignarro L.J., Degnan J.N., Baricos W.H., Kadowitz P.J., Wolin M.S. Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochimica et Biophysica Acta. 718(1):1982;49-59.
13. Foerster J., Harteneck C., Malkewitz J., Schultz G., Koesling D. A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. European Journal of Biochemistry. 240(2):1996;380-386.
14. Wedel B., Humbert P., Harteneck C., Foerster J., Malkewitz J., Bohme E., Schultz G., Koesling D. Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proceedings of National Academy of Sciences, USA. 91(7):1994;2592-2596.
15. Zhao Y., Marletta M.A. Localization of the heme binding region in soluble guanylate cyclase. Biochemistry. 36(50):1997;15959-15964.
16. Ignarro L.J. Mechanism of action of nitric oxide: heme-dependent activation of guanylate cyclase represents a unifying signal transduction mechanism. Japanese Journal of Pharmacology. 58(Suppl. 2):1992;207P-212P.
17. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Molecular Pharmacology. 48(2):1995;184-188.
18. Schrammel A., Behrends S., Schmidt K., Koesling D., Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Molecular Pharmacology. 50(1):1996;1-5.
19. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. British Journal of Pharmacology. 116(3):1995;1973-1978.
20. Friebe A., Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Molecular Pharmacology. 53(1):1998;123-127.
21. Stone J.R., Marletta M.A. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chemistry and Biology. 5(5):1998;255-261.
22. Denninger J.W., Schelvis J.P., Brandish P.E., Zhao Y., Babcock G.T., Marletta M.A. Interaction of soluble guanylate cyclase with YC-1: kinetic and resonance Raman studies. Biochemistry. 39(14):2000;4191-4198.
23. Margulis A., Sitaramayya A. Rate of deactivation of nitric oxide-stimulated soluble guanylate cyclase: influence of nitric oxide scavengers and calcium. Biochemistry. 39(5):2000;1034-1039.
24. Nakane M., Saheki S., Kuno T., Ishii K., Murad F. Molecular cloning of a cDNA coding for 70 kilodalton subunit of soluble guanylate cyclase from rat lung. Biochemical and Biophysical Research Communications. 157(3):1988;1139-1147.
25. O'Reilly D.R. Use of baculovirus expression vectors. Methods in Molecular Biology. 1997;235-246.
26. Hoenicka M., Becker E.M., Apeler H., Sirichoke T., Schroder H., Gerzer R., Stasch J.P. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. Journal of Molecular Medicine. 77(1):1999;14-23.
27. Gupta S., Moreland R., Yang S., Gallant C., Goldstein I., Traish A. The expression of functional postsynaptic alpha2-adrenoceptors in the corpus cavernosum smooth muscle. British Journal of Pharmacology. 123(6):1998;1237-1245.
28. Hussain A.S., Marks G.S., Brien J.F., Nakatsu K. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one (ODQ) inhibits relaxation of rabbit aortic rings induced by carbon monoxide, nitric oxide, and glyceryl trinitrate. Canadian Journal of Physiology and Pharmacology. 75(8):1997;1034-1037.
29. Zhao Y., Brandish P.E., DiValentin M., Schelvis J.P., Babcock G.T., Marletta M.A. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry. 39(35):2000;10848-10854.
30. Friebe A., Mullershausen F., Smolenski A., Walter U., Schultz G., Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Molecular Pharmacology. 54(6):1998;962-967.
31. Wegener J.W., Closs E.I., Forstermann U., Nawrath H. Failure of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) to inhibit soluble guanylyl cyclase in rat ventricular cardiomyocytes. British Journal of Pharmacology. 127(3):1999;693-700.
32. Stasch J.P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Plei B.U., Schroder H., Schroeder W., Stahl E., Steinke W., Straub A., Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature. 410(6825):2001;212-215.
33. Straub A., Stasch J.P., Alonso-Alija C., Benet-Buchholz J., Ducke B., Feurer A., Furstner C. NO-independent stimulators of soluble guanylate cyclase. Bioorganic and Medicinal Chemistry Letters. 11(6):2001;781-784.
34. Moreland R.B., Hsieh G., Nakane M., Miller L.N., Chang R., Kolasa T., Sullivan J.P., Brioni J.D. Novel soluble guanylate cyclase activators A-344905 and A-350619 activate sGC in vitro and facilitate erection in rats. Journal of Urology. 167(Suppl. 4):2002;239. (Abstract 938).
35. Nakane M., Hsieh G., Miller L.N., Chang R., Terranova M.A., Moreland R.B., Kolasa T., Brioni J.D. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. International Journal of Impotence Research. 14(2):2002;121-127.
36. Hsieh G., O'Neill A.B., Nakane M., Moreland R.B., Brioni J.D. YC-1, a soluble guanylate cyclase activator, potentiates the NO-cGMP pathway and facilitates penile erection in rats. Journal of Urology. 167(Suppl. 4):2002;239. (Abstract 939).
37. Mizusawa H., Hedlund P., Brioni J.D., Sullivan J.P., Andersson K.E. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. Journal of Urology. 167(5):2002;2276-2281.